FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC 3 program

Journal of Hepatology

Volumn 54, Issue 2, 2011, Pages 227-235

  Poynard, Thierry ^a   Munteanu, Mona ^a   Colombo, Massimo ^b   Bruix, Jordi ^c   Schiff, Eugene ^d   Terg, Ruben ^e   Flamm, Steven ^f   Moreno Otero, Ricardo ^g   Carrilho, Flair ^h   Schmidt, Warren ⁱ   Berg, Thomas ^j   McGarrity, Thomas ^k   Heathcote, E Jenny ^l   Gonales, Fernando ^m   Diago, Moises ⁿ   Craxi, Antonio ^o   Silva, Marcelo ^p   Boparai, Navdeep ^q   Griffel, Louis ^q   Burroughs, Margaret ^q   Brass, Clifford ^q   Albrecht, Janice ^q   more..

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Hospital Municipal de Gastroenterologia Dr Bonorino Udaondo   (Argentina)

^f NORTHWESTERN UNIVERSITY   (United States)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^l UNIVERSITY HEALTH NETWORK   (Canada)

^m UNIVERSITY OF CAMPINAS   (Brazil)

ⁿ HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^o UNIVERSITY OF PALERMO   (Italy)

^p UNIVERSIDAD AUSTRAL   (Argentina)

^q MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Biomarkers; Cirrhosis; Early virologic response; Fibrosis; Hepatitis C; Non responder; Relapser; Treatment failure

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HAPTOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG EFFICACY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HISTOLOGY; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INVASIVE PROCEDURE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION STUDY; VIRUS HEPATITIS;

ADULT; ALANINE TRANSAMINASE; BIOPSY; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 78751570909     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.06.038     Document Type: Article

References (36)

1. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
2. D.S. Manning, and N.H. Afdhal Diagnosis and quantitation of fibrosis Gastroenterology 134 2008 1670 1681
3. P. Halfon, M. Munteanu, and T. Poynard FibroTest-ActiTest as a non-invasive marker of liver fibrosis Gastroenterol Clin Biol 32 2008 22 38
4. T. Poynard, M. Munteanu, F. Imbert-Bismut, F. Charlotte, D. Thabut, and S. Le Calvez Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C Clin Chem 50 2004 1344 1355
5. Y. Ngo, M. Munteanu, D. Messous, F. Charlotte, F. Imbert-Bismut, and D. Thabut A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C Clin Chem 52 2006 1887 1896
6. H. Fontaine, K. Petitprez, F. Roudot-Thoraval, and J.C. Trinchet Guidelines for the diagnosis of uncomplicated cirrhosis Gastroenterol Clin Biol 31 2007 504 509
7. La Haute Autorité de Santé (HAS) in France. The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers. [accessed 08.08].
8. T. Poynard, F. Imbert-Bismut, V. Ratziu, S. Chevret, C. Jardel, and J. Moussalli Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial J Viral Hepat 9 2002 128 133
9. T. Poynard, J. McHutchison, M. Manns, R.P. Myers, and J. Albrecht Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin Hepatology 38 2003 481 492
10. C. D'Arondel, M. Munteanu, J. Moussalli, V. Thibault, S. Naveau, and A. Simon A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers J Viral Hepat 13 2006 182 189
11. K. Patel, Y. Benhamou, E.M. Yoshida, K.D. Kaita, S. Zeuzem, and M. Torbenson An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C J Viral Hepat 16 2009 178 186
12. T. Poynard, M. Colombo, J. Bruix, E. Schiff, R. Terg, and S. Flamm The Epic Study Group. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
13. F. Imbert-Bismut, D. Messous, V. Thibaut, R.B. Myers, A. Piton, and D. Thabut Intralaboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors Clin Chem Lab Med 42 2004 323 333
14. T. Poynard, F. Imbert-Bismut, M. Munteanu, D. Messous, R.P. Myers, and D. Thabut Comp Hepatol 3 2004 8
15. F. Imbert-Bismut, D. Messous, A. Raoult, T. Poynard, J.J. Bertrand, and P.A. Marie Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and Modular DP (Roche Diagnostics) analysers: application to component assays of Fibrotest and Actitest Ann Biol Clin (Paris) 63 2005 305 313
16. T. Poynard, V. Ratziu, S. Naveau, D. Thabut, F. Charlotte, and D. Messous Comp Hepatol 4 2005 10
17. P. Bedossa, and T. Poynard For the METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C Hepatology 24 1996 289 293
18. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
19. Zhou X, Obuchowski N, McClish D. Statistical Methods in Diagnostic Medicine. New York, NY: John Wiley and Sons; 2002. p. 235.
20. T. Poynard, P. Halfon, L. Castera, M. Munteanu, F. Imbert-Bismut, and V. Ratziu Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages Clin Chem 53 2007 1615 1622
21. J. Lambert, P. Halfon, G. Penaranda, P. Bedossa, P. Cacoub, and F. Carrat How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited Clin Chem 54 8 2008 Aug 1372 1378
22. T. Poynard, P. Halfon, L. Castera, F. Charlotte, B. Le Bail, and M. Munteanu Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation Aliment Pharmacol Ther 25 2007 733 739
23. T. Poynard, M. Munteanu, R. Morra, Y. Ngo, F. Imbert-Bismut, and D. Thabut Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update Gastroenterol Clin Biol 32 2008 8 21
24. Hintze JL. NCSS 2007 user guide. Kaysville, UT: Number cruncher statistical systems software NCSS; 2007.
25. Y. Ngo, Y. Benhamou, V. Thibault, P. Ingiliz, M. Munteanu, and P. Lebray PLoS One 3 2008 e2573
26. S. Naveau, G. Gaudé, A. Asnacios, H. Agostini, A. Abella, and N. Barri-Ova Diagnostic and prognostic values of non-invasive biomarkers of fibrosis in patients with alcoholic liver disease Hepatology 49 2009 97 105
27. P. Brissot, and F. de Bels Current approaches to the management of hemochromatosis Hematol Am Soc Hematol Educ Program 2006 36 41
28. T. Poynard, M. Munteanu, Y. Ngo, L. Castera, P. Halfon, and V. Ratziu ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure Gastroenterol Clin Biol 34 2010 388 396
29. P. Bedossa, D. Dargre, and V. Paradis Sampling variability of liver fibrosis in chronic hepatitis C Hepatology 38 2003 1449 1457
30. A.M. Di Bisceglie, M.L. Shiffman, G.T. Everson, K.L. Lindsay, J.E. Everhart, and E.C. Wright Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
31. T. Poynard, and V. Ratziu Prolonged therapy for hepatitis C with low-dose peginterferon N Engl J Med 360 2009 1152
32. Afdhal NH, Levine R, Brown R, Freilich B, O'Brien M, Brass C. Colchicine versus peg-interferon alfa 2b long-term therapy: results of the 4-year COPILOT Trial. J Hepatol 2008;48:S4 (abstract).
33. 3 cirrhosis maintenance trial J Hepatol 50 Suppl 1 2009 S22
34. T. Poynard, J. McHutchison, Z. Goodman, M.H. Ling, and J. Albrecht For the ALGOVIRC Project Group. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 31 2000 211 218
35. B.J. Veldt, E.J. Heathcote, H. Wedemeyer, J. Reichen, W.P. Hofmann, and S. Zeuzem Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 2007 677 684
36. T. Poynard, V. Ratziu, J. McHutchison, M. Manns, Z. Goodman, and S. Zeuzem Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C Hepatology 38 2003 75 85